Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BioPsychoSocial Medicine
Published in: BioPsychoSocial Medicine 1/2020

01-12-2020 | Heart Failure | Research

Higher galectin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failure

Authors: Monika Sadlonova, Thomas Meyer, Lutz Binder, Rolf Wachter, Frank Edelmann, Christoph Herrmann-Lingen

Published in: BioPsychoSocial Medicine | Issue 1/2020

Login to get access

Abstract

Background

Galectin-3 promotes the proliferation of neural progenitor cells and is engaged in cell-cell adhesion, cell-matrix interactions, and macrophage activation. In addition, in patients with heart failure this carbohydrate-binding protein is a known prognostic marker for cardiovascular mortality. However, its association with psychological variables has not been investigated so far.

Methods

Using data from the multicenter, observational Diast-CHF (Diagnostic Trial on Prevalence and Clinical Course of Diastolic Dysfunction and Heart Failure) trial, we studied in participants with cardiovascular risk factors (n = 1260, age 66.7 ± 8.0 years, males 51%, left ventricular ejection fraction 60.0 ± 8.1%) the relationship between serum concentrations of galectin-3 and anxiety. Galectin-3 levels were measured by means of a sandwich enzyme-linked immunosorbent assay, and anxiety was assessed using the Hospital Anxiety and Depression Scale (HADS).

Results

In univariate analysis, there was a weak but significant inverse correlation between galectin-3 and HADS anxiety (rho = − 0.076; p = 0.008). Linear regression models adjusted for sex, age, body-mass index, estimated glomerular filtration rate, left ventricular ejection fraction, 6-min walking distance, the 36-item Short-Form Health Survey (SF-36) subscale physical functioning, and known biomarkers for heart failure confirmed that serum galectin-3 significantly and independently predicted self-rated anxiety (B = -2.413; 95%CI = -2.413–-4.422; p = 0.019).

Conclusion

In patients with cardiovascular risk factors, serum concentrations of galectin-3 showed an inverse association with anxiety, which was independent of both the severity of physical impairment and established risk factors for the progression of heart failure.
Literature
1.
Meyer T, Buss U, Herrmann-Lingen C. Role of cardiac disease severity in the predictive value of anxiety for all-cause mortality. Psychosom Med. 2010;72:9–15.PubMedCrossRef
2.
Meyer T, Hussein S, Lange HW, Herrmann-Lingen C. Anxiety is associated with a reduction in both mortality and major adverse cardiovascular events five years after coronary stenting. Eur J Prev Cardiol. 2015;22:75–82.PubMedCrossRef
3.
Frasure-Smith N, Lespérance F. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatry. 2008;65:62–71.PubMedCrossRef
4.
Martens EJ, de Jonge P, Na B, Cohen BE, Lett H, Whooley MA. Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease: The Heart and Soul Study. Arch Gen Psychiatry. 2010;67:750–8.PubMedCrossRef
5.
Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol. 2010;56:38–46.PubMedCrossRef
6.
Watkins LL, Koch GG, Sherwood A, Blumenthal JA, Davidson JR, O'Connor C, Sketch MH. Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease. J Am Heart Assoc. 2013;2:e000068.PubMedPubMedCentralCrossRef
7.
Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 2014;77:439–48.PubMedCrossRef
8.
Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015;170:1105–15.PubMedPubMedCentralCrossRef
9.
Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 1989;13:1534–9 Erratum in: J Am Coll Cardiol. 1989;14:812.PubMedCrossRef
10.
Hall C, Rouleau JL, Moyè L, de Champlain J, Bichet D, Klein M, Sussex B, Packer M, Rouleau J, Arnold MO. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994;89:1934–42.PubMedCrossRef
11.
Alehagen U, Dahlström U, Rehfeld JF, Goetze JP. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA. 2011;305:2088–95.PubMedCrossRef
12.
Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail. 2011;4:613–20.PubMedCrossRef
13.
Herrmann-Lingen C, Binder L, Klinge M, Sander J, Schenker W, Beyermann B, von Lewinski D, Pieske B. High plasma levels of N-terminal pro-atrial natriuretic peptide associated with low anxiety in severe heart failure. Psychosom Med. 2003;65:517–22.PubMedCrossRef
14.
Meyer T, Herrrmann-Lingen C, Chavanon ML, Nolte K, Pasedach CA, Binder L, Pieske B, Hasenfuss G, Wachter R, Edelmann F. Higher plasma levels of MR-pro-atrial natriuretic peptide are linked to less anxiety: results from the observational DIAST-CHF study. Clin Res Cardiol. 2015;104:574–81.PubMedCrossRef
15.
Fangauf SV, Herbeck Belnap B, Meyer T, Albus C, Binder L, Deter HC, Ladwig KH, Michal M, Ronel J, Rothenberger A, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology. 2018;96:188–94.PubMedCrossRef
16.
Sadlonova M, Meyer T, Binder L, Edelmann F, Wachter R, Herrmann-Lingen C. Higher plasma levels of CT-proAVP are linked to less anxiety in men but not women with cardiovascular risk factors: Results from the observational Diast-CHF study. Psychoneuroendocrinology. 2019;101:272–7.PubMedCrossRef
17.
Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Düngen HD, Tschöpe C, et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail. 2015;17:214–23.PubMedCrossRef
18.
Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60:1249–56.PubMedPubMedCentralCrossRef
19.
van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48:217–24.CrossRef
20.
Lok DJ, van der Meer P, de la Porte PWBA, Lipsic E, van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323–8.PubMedPubMedCentralCrossRef
21.
Lok DJ, Lok SI, de la Porte PWBA, Badings E, Lipsic E, van Wijngaarden J, de Boer RA, van Veldhuisen DJ, van der Meer P. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013;102:103–10.PubMedCrossRef
22.
Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12:826–32.PubMedPubMedCentralCrossRef
23.
de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60–8.PubMedCrossRef
24.
van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, de Boer RA, Asselbergs FW, Wajon EMCJ, Orsel JG, Boersma E, et al. Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure. J Am Heart Assoc. 2017;6:e003700.PubMedPubMedCentral
25.
Dumić J, Barisić K, Flögel M, Lauc G. Galectin-3 decreases in mice exposed to immobilization stress. Stress. 2000;3:241–6.PubMedCrossRef
26.
de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11:811–7.PubMedCrossRef
27.
Krześlak A, Lipińska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett. 2004;9:305–28.PubMed
28.
Sundblad V, Croci DO, Rabinovich GA. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues. Histol Histopathol. 2011;26:247–65.PubMed
29.
deFilippi CR, Christenson RH. Evolving role of galectin-3 as a cardiac biomarker: heart failure with preserved ejection fraction and renal function, important pieces of the puzzle. JACC Heart Fail. 2015;3:253–65.PubMedCrossRef
30.
Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 2011;89:265–72.PubMedCrossRef
31.
Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121–8.PubMedCrossRef
32.
Sartim AG, Sartim MA, Cummings RD, Dias-Baruffi M, Joca SR. Impaired emotional response to stress in mice lacking galectin-1 or galectin-3. Physiol Behav. 2020;220:112862.PubMedCrossRef
33.
Stajic D, Selakovic D, Jovicic N, Joksimovic J, Arsenijevic N, Lukic ML, Rosic G. The role of galectin-3 in modulation of anxiety state level in mice. Brain Behav Immun. 2019;78:177–87.PubMedCrossRef
34.
Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen HD, Lüers C, Binder L, Herrmann-Lingen C, Gelbrich G, Hasenfuss G, Pieske B, Wachter R. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail. 2010;12:1309–16.PubMedPubMedCentralCrossRef
35.
Herrmann-Lingen C, Buss U, Snaith RP. Hospital Anxiety and Depression Scale – Deutsche Version (HADS-D). 3rd ed. Bernd: Hans Huber Publishing Company; 2011.
36.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.PubMedCrossRef
37.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.PubMedCrossRef
38.
Christenson RH, Duh SH, Wu AHB, Smith A, Abel G, deFilippi CR, Wang S, Adourian A, Adiletto C, Gardiner P. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem. 2010;43:683–90.PubMedCrossRef
39.
Hrynchyshyn N, Jourdain P, Desnos M, Diebold B, Funck F. Galectin-3: A new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis. 2013;106:541–6.PubMedCrossRef
40.
Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, Schenk J. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl. 1999;230:177–81.PubMedCrossRef
41.
Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem. 2003;49:976–9.PubMedCrossRef
42.
Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem. 2004;50:234–6.PubMedCrossRef
43.
Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112–9.CrossRefPubMed
44.
Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008;19:43–9.PubMedCrossRef
45.
Dabelic S, Flögel M, Dumic J. Hydrocortisone and dexamethasone affect galectin-3 expression. Periodicum Biologorum. 2005;107(2):175–81.
46.
Ikemori RY, Machado CM, Furuzawa KM, Nonogaki S, Osinaga E, Umezawa K, de Carvalho MA, Verinaud L, Chammas R. Galectin-3 up-regulation in hypoxic and nutrient deprived microenvironments promotes cell survival. PLoS One. 2014;9:e111592.PubMedPubMedCentralCrossRef
47.
Hsu DK, Yang RY, Pan Z, Yu L, Salomon DR, Fung-Leung WP, Liu FT. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol. 2000;156:1073–83.PubMedPubMedCentralCrossRef
48.
Rahimian R, Béland LC, Kriz J. Galectin-3: mediator of microglia responses in injured brain. Drug Discov Today. 2018;23:375–81.PubMedCrossRef
49.
Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, Shirolkar SC, Donahue M, Kitzman DW, Zannad F, et al. Galectin-3 in ambulatory patients with heart failure: Results from the HF-ACTION study. Circ Heart Fail. 2012;5:72–8.PubMedCrossRef
50.
Meijers WC, Januzzi JL, deFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, de Boer RA. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. Am Heart J. 2014;167:853–60.PubMedCrossRef
51.
Meyer T, Chavanon ML, Herrmann-Lingen C, Roggenthien M, Nolte K, Pieske B, Wachter R, Edelmann F. Elevated plasma C-terminal endothelin-1 precursor fragment concentrations are associated with less anxiety in patients with cardiovascular risk factors. Results from the observational DIAST-CHF study. PLoS One. 2015;10:e0136739.PubMedPubMedCentralCrossRef
52.
Meyer T, Herrmann-Lingen C, Chavanon ML, Pieske B, Wachter R, Edelmann F. Plasma mid-regional pro-adrenomedullin levels are inversely associated with anxiety but unrelated to depression: Results from the observational DIAST-CHF study in patients with cardiovascular risk factors. Psychoneuroendocrinology. 2015;62:227–32.PubMedCrossRef
Metadata
Title
Higher galectin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failure
Authors
Monika Sadlonova
Thomas Meyer
Lutz Binder
Rolf Wachter
Frank Edelmann
Christoph Herrmann-Lingen
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BioPsychoSocial Medicine / Issue 1/2020
Electronic ISSN: 1751-0759
DOI
https://doi.org/10.1186/s13030-020-00195-7

Other articles of this Issue 1/2020

BioPsychoSocial Medicine 1/2020 Go to the issue

Research

The accuracy of delirium assessment by cardiologists treating heart failure inpatients: a single center retrospective survey

Research

Physical activity and disability in patients with noncardiac chest pain: a longitudinal cohort study

Review

The prognosis and prevention measures for mental health in COVID-19 patients: through the experience of SARS

Correction

Correction to: Very long chain fatty acids are an important marker of nutritional status in patients with anorexia nervosa: a case control study

Research

Post-traumatic stress symptoms in hemodialysis patients with MERS-CoV exposure

Research

Effect of relaxation therapy on benzodiazepine use in patients with medically unexplained symptoms